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a b s t r a c t
This study was designed to investigate the impact of macular carotenoid supplementation on the spatial
profile of macular pigment (MP) in subjects where the profile does not exhibit the typical central peak
(i.e. peaked MP at foveal epicentre). Thirty one healthy subjects with such atypical MP spatial profiles
were assigned to one of three intervention groups: Group 1: (n ¼ 11), 20 mg/day lutein (L), 2 mg/day
zeaxanthin (Z); Group 2: (n ¼ 10), 10 mg/day meso-zeaxanthin (MZ), 10 mg/day L, 2 mg/day Z; Group 3:
(n ¼ 10), 17 mg/day MZ, 3 mg/day L, 2 mg/day Z. Subjects were instructed to take one capsule daily over
an 8-week period. MP at 0.25, 0.5, 1, 1.75and 3 was measured using customized-heterochromatic
flicker photometry at baseline, four weeks and 8 weeks. Over the study period, we report no statisti-
cally significant increase in MP at any eccentricity in Group 1 (p > 0.05, for all eccentricities). There was
a trend towards an increase in MP at all eccentricities in Group 2, with a significant increase found at
0.25 and 0.50 (p ¼ 0.000 and p ¼ 0.016, respectively). There was a statistically significant increase
evident in MP at 0.25 in Group 3 (p ¼ 0.005), but at no other eccentricity (p > 0.05, for all other). We
report that the typical central peak of MP can be realised in subjects with atypical spatial profiles,
following supplementation with a preparation containing all three macular carotenoids, but not with
a supplement lacking MZ. The implications of our findings, in terms of visual performance and/or
a (photo)-protective effect, warrant additional study.
 2012 Published by Elsevier Ltd.
1. Introduction
The central retina, known as the macula, is responsible for
colour and fine-detail vision (Hirsch and Curcio, 1989). A pigment,
composed of the carotenoids, lutein (L), zeaxanthin (Z), and meso-
zeaxanthin (MZ), (Bone et al., 1997; Johnson et al., 2005) accumu-
late at the macula where they are collectively known as macular
pigment (MP). MP is a blue light filter (Snodderly et al., 1984b) and
a powerful antioxidant, (Khachik et al., 1997) and is therefore
believed to protect against age-related macular degeneration
(AMD), which is now the most common cause of blind registration
in the westernworld (Klaver et al., 1998). In addition, MP’s putative
ability to enhance visual performance and comfort is also of
interest (Bartlett and Eperjesi, 2008; Engles et al., 2007; Hammond
and Wooten, 2005; Kvansakul et al., 2006; Loughman et al., 2010;
Nolan et al., 2011; Rodriguez-Carmona et al., 2006; Stringham and
Hammond, 2007, 2008; Stringham et al., 2004; Wooten and
Hammond, 2002). Q1
Z and MZ are the predominant carotenoid in the foveal region,
whereas L predominates in the parafoveal region (Bone et al., 1988;
Snodderly et al., 1991). The concentration of MZ peaks centrally,
with the MZ:Z ratio of 0.82 (approximately) in the central retina
(with in 3 mm of the fovea) and 0.25 in the peripheral retina
(11e21 mm from the fovea) (Bone et al., 1997). The above obser-
vations are most probably attributable to the fact that retinal MZ is
produced primarily by isomerization of retinal L, (Johnson et al.,
2005) thus accounting for lower relative levels of L, and higher
relative levels of MZ, in the central macula, and vice versa in the
peripheral macula, and would also explain why MZ accounts for
about one third of total MP, (Bone et al., 1993) in spite of its absence
or low concentrations in a typical diet.
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MP represents the most conspicuous accumulation of caroten-
oids in the human body; however, its concentration has been
shown to vary dramatically among individuals (Hammond et al.,
1997). Typical MP profiles generally peak at the centre of the
macula and decreases in concentrationwith increasing eccentricity
out to the parafovea (Bone et al., 1988; Snodderly et al., 1984a).
However, as mentioned above, variations in the distribution of MP
have been reported (Berendschot and van Norren, 2006; Delori
et al., 2006; Kirby et al., 2009). Recently, for example, it has been
shown that atypical MP spatial profiles (i.e. those not exhibiting
a typical central peak) are present in some individual MP profiles.
More importantly, it has been confirmed that these atypical profiles
are real and reproducible features of the MP spatial profile, when
measured using customized-heterochromatic flicker photometry
(cHFP, a validated technique for measuring MP) (Kirby et al., 2009).
The importance of such variations, if any, in the spatial profile of MP
(e.g. the absence of a typical central peak) is not yet known, butmay
be related to the putative protective role of this pigment. For
example, reduced MPOD at the centre of the macula may be
associated with increased risk of developing AMD (given the lower
antioxidant activity and short-wavelength light filtering capacity
of such an individual, when compared to an individual with
a typical central peak) (Trieschmann et al., 2003). Also, a recent
study by our research group has shown that 12% (58 subjects out of
a sample database of 484 subjects) of the healthy Irish population
exhibit a reproducible atypical MP spatial profile (characterized by
the lack of a typical central peak) and that such atypical MP spatial
profiles are more common in older subjects and in cigarette
smokers (two of the established risk factors for AMD) (Kirby
et al., 2010).
In brief, the current study has taken advantage of a unique
opportunity, by inviting subjects from the above mentioned data-
base (n ¼ 58), (Kirby et al., 2010) who were identified, and
confirmed, as exhibiting such an atypical MP spatial profile (see
Fig. 1).
2. Methods
2.1. Subjects and study design
Fifty eight subjects with atypical MP spatial profiles (identified
from our master MP database; n ¼ 484) were invited to revisit our
vision science laboratories at the Waterford Institute of Technology
(WIT) and Dublin Institute of Technology (DIT), Ireland, to confirm
the presence of their atypical MP spatial profile. Of the forty
subjects who agreed to come back for testing, thirty subjects were
confirmed as still exhibiting an atypical MP profile as defined by
our criteria (i.e. MPOD at 0.25 did not exceed MPOD at 0.5 of
eccentricity by more than 0.04 optical density units) generated for
the purpose of this study, and were therefore enrolled into the 8-
week supplementation trial with one of three different macular
carotenoid formulations (see below).
Of the nine subjects who no longer exhibited an MP spatial
profile sufficiently atypical for inclusion in the current study,
because of our strict and predefined criteria, seven did exhibit
a persistently atypical profile. With respect to the other two
subjects, possible explanations as to why they no longer exhibited
the previously observed atypical MP profile may rest on the
interval between original testing and recall for the purpose of
this study and/or changes in dietary habits (including possible
supplementation).
All subjects signed an informed consent document and the
experimental measures conformed to the Declaration of Helsinki.
The study was reviewed and approved by the Research Ethics
Committees of Waterford Institute of Technology, Waterford,
Ireland, and Dublin Institute of Technology, Dublin, Ireland. Inclu-
sion criteria for participation in this studywere as follows:MPOD at
0.25 did not exceedMPOD at 0.5 of eccentricity bymore than 0.04
optical density units (thereby defining “atypical” MP spatial profile
for the purpose of this study); no presence of ocular pathology;
corrected distance visual acuity (CDVA) 20/60 or better in the study
eye; no current or prior use of supplements containing L and/or
Z and/or MZ.
This was a randomized and double blind clinical trial with three
interventions. Subjects were randomly assigned into one of the
three groups as follows: Group 1: high L group (n ¼ 10; L ¼ 20 mg/
day, Z ¼ 2 mg/day); Group 2: combined carotenoid group (n ¼ 10;
MZ ¼ 10 mg/day, L ¼ 10 mg/day, Z ¼ 2 mg/day); Group 3: high MZ
group (n ¼ 10; MZ ¼ 17 mg/day, L ¼ 3 mg/day, Z ¼ 2 mg/day).
All subjects were instructed to take one capsule per day with
a meal for 8 weeks. Significant efforts were made to ensure
compliance to the study intervention. Weekly text messages and
phone calls were made by the research team. In addition, subjects
were requested to return their supplement packs at their exit visit,
and compliance was checked by tablet counting at this visit.
MPOD, including its spatial profile, i.e. at 0.25, 0.5, 1, 1.75, 3,
was measured at baseline, four weeks and 8 weeks. The right eye
was chosen as the study eye for all subjects, with the exception of
one subject whose right CDVA did not meet the criteria for MP
testing, and the left eye for that subject was, therefore, chosen as
the study eye.
Demographic, lifestyle and vision informationwas also collected
from each subject as follows: name; contact information; age; sex;
smoking habits; medication and vision case history. CDVA was
measured by logMAR chart. A subject’s weekly intake of carotenoid
rich foods (eggs, broccoli, corn, dark leafy vegetables) were
inputted into the “L/Z screener” to give a carotenoid diet ‘score’.
Values were weighted for frequency of intake of the food and for
the bioavailability of L and Z with in these foods and a ranking
score reflecting the relative intakes was generated. Evaluation of
the L/Z screener against the Willet food frequency questionnaire
yielded a positive correlation that was strongly significant
(p < 0.01). The range of scores from the L/Z screener is 0e75. After
adding foods with known concentrations of L and Z into the
screener, the following estimates were made. Low dietary
carotenoid intake score is from 0 to 15 (i.e. 2 mg/d); medium
dietary carotenoid intake score is from 16 to 30 (i.e. between >2
Retinal eccentricity
































Fig. 1. Mean (SD) macular pigment optical density spatial profile for the entire study
group (n ¼ 30) at baseline. The smooth line drawn through the data was achieved
using our graphic software Sigma Plot 8.
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and 13 mg/day); high dietary carotenoid intake score is from 31 to
75 (i.e. >13 mg/day).
2.2. Measurement of macular pigment optical density
The spatial profile of MP was measured using the Macular
Densitometer, a HFP instrument that is slightly modified from
a device described by Wooten and Hammond (2005). A detailed
discussion of the principle of HFP and its customization to accu-
rately measure MP has also been described by Kirby et al. (2009).
All subjects in this study previously had their MP spatial profile
measured with the Macular Densitometer using the cHFP tech-
nique. In addition, further training was provided prior to testing.
Therefore, all subjects in the current study were experienced with
respect to the device and testing procedure. In order tomeasure the
spatial profile of MP, we performed measurements at the following
degrees of retinal eccentricity: 0.25, 0.5, 1, 1.75, 3 and 7 (the
reference point) obtained using the following sized target diame-
ters; 30 min, 1, 2, 3.5, 1 and 2, respectively. Stimulus 5, our 3
target, was a 1 diameter disc with its centre located 3 from a black
fixation point (i.e. the average of the inner arc which defines the
disc at 2.5 and the outer arc which defines the disc at 3.5).
Stimulus 6, our reference point, is a 2 diameter disc with its centre
located 7 from a red fixation point (i.e. the average of the inner arc
which defines the disc at 6 and the outer arc which defines the
disc at 8) as MPOD at this location is optically undetectable and its
distribution at this location is essentially flat. Measurement of
the spatial profile of MP using cHFP has previously been shown to
be highly reproducible (ICC ¼ 0.93e0.96), and therefore does
not account for change identified in the spatial profile of MP
over time (either following, or without, dietary modification/
supplementation) when measured using this technique (Kirby
et al., 2009, 2010).
2.3. Statistical analysis
The statistical software package PASW Statistics 17.0 (SPSS Inc.,
Chicago, Illinois, USA) was used for analysis and Sigma Plot 8.0
(Systat Software Inc., Chicago, Illinois, USA) was used for graphical
presentations. All quantitative variables investigated exhibited
a normal distribution. Means  SDs are presented in the text and
tables. Statistical comparisons of the three different intervention
groups, at baseline, were conducted using oneway ANOVA and chi-
square analysis, as appropriate.
We conducted repeated measures ANOVA for MPOD, including
its spatial profile, for each intervention group, including each study
visit, using a general linear model approach, with age as a covariate
(as age was significantly different between the groups at baseline,
see below). Bonferroni correction was applied as appropriate. We
used the 5% level of significance throughout our analysis.
3. Results
3.1. Baseline findings
The demographic, lifestyle, CDVA, and MPOD data of all thirty
one subjects recruited into the study, and divided by study arm (i.e.
Group 1, Group 2, Group 3), are summarized in Table 1. As seen from
this table, most variables under investigation did not differ signif-
icantly between these groups at baseline (p > 0.05, for said vari-
ables). However, a significant baseline difference between these
groups with respect to age (p < 0.01) was identified, with Group 3
having a significantly lower mean age when compared to Groups 1
and 2, and age was therefore controlled for throughout the
remainder of the analysis.
3.2. Change in MPOD over 8-week supplementation period
As seen in Table 2, increases in MPOD at 0.25 and 0.5 were
statistically significant in Group 2. Similarly, a significant increase
in MPOD at 0.25 was seen in Group 3. Of note, after Bonferroni
correction for multiple testing, the MPOD increase seen at 0.25 in
Group 2 was the only observed increase to remain statistically
significant.
Changes in MPOD values over time, for each subject and for all
eccentricities measured, are presented in Table 3. Change in the
spatial profile of MPOD for each group is illustrated in Figs. 2e4.
These figures graphically represent mean MPOD spatial profile for
each group at baseline (pre supplementation) and at 8 weeks (post
supplementation).
At 0.25 of eccentricity, a MPOD increase of >10% was seen in 4
(40%), 10 (100%) and 8 (80%) subjects in Groups 1, 2, and 3,
respectively. Further, at this eccentricity, the average increase in
MPOD (measured in optical density units) was 0.031 (13%), 0.182
(102%), and 0.094 (22%) in Groups 1, 2 and 3, respectively. At 0.5 of
eccentricity, a MPOD increase of >10% was seen in 3 (30%), 7 (70%)
and 5 (50%) subjects in Groups 1, 2 and 3, respectively. Further, at
this eccentricity, the average increases in MPOD (measured in
optical density units) was 0.02 (13%), 0.079 (27%), and 0.019 (6%),
for these Groups, respectively.
4. Discussion
This is the first study designed to investigate the effect
of macular carotenoid supplementation, with three different
Table 1









Age 47  14 51  11b 56  11b 35  10b
Sex
Male 9 3 3 3
Female 21 7 7 7
Smoking habitsc
Never smoker 19 7 7 5
Ex-smoker 10 2 3 5
Current smoker 1 1 0 0
Positive FH of AMDd 8 3 2 3
Diet scoree 27  14 34  15 25  14 22  13
Aided Visual acuity 105  8 105  8 106  6 107  4
MPOD
0.25 0.45  0.21 0.46  0.21 0.41  0.27 0.48  0.16
0.5 0.46  0.21 0.46  0.23 0.44  0.26 0.48  0.15
1 0.26  0.19 0.20  0.19 0.26  0.23 0.32  0.12
1.75 0.14  0.10 0.15  0.10 0.18  0.10 0.11  0.09
3 0.14  0.10 0.14  0.11 0.16  0.12 0.12  0.08
a n ¼ sample size.
b p < 0.01.
c Smoking habits: ex-smoker ¼ smoked 100 cigarettes in lifetime but none in
last 12 months; current smoker ¼ smoked 100 cigarettes in lifetime and at least 1
cigarette per week in last 12 months.
d Positive FH of AMD: positive family history of age-related macular degeneration
(self reported). Values represent mean  standard deviation; MPOD ¼ macular
pigment optical density; 0.25 ¼ MPOD measured at 0.25 retinal eccentricity;
0.5 ¼MPODmeasured at 0.5 retinal eccentricity; 1 ¼MPODmeasured at 1 retinal
eccentricity; 1.75 ¼ MPOD measured at 1.75 retinal eccentricity; 3 ¼ MPOD
measured at 3 retinal eccentricity; Group 1: high L group (L ¼ 20 mg/day,
Z ¼ 2 mg/day); Group 2: combined carotenoid group (MZ ¼ 10 mg/day,
L ¼ 10 mg/day, Z ¼ 2 mg/day); Group 3: high MZ group (MZ ¼ 17 mg/day,
L ¼ 3 mg/day, Z ¼ 2 mg/day).
e A subject’s weekly intake of carotenoid rich foods (eggs, broccoli, corn, dark
leafy vegetables) were inputted into an L/Z screener to give a carotenoid diet ‘score’.
Values were weighted for frequency of intake of the food and for the bioavailability
of L and Z within these foods and an arbitrary score were generated and used to
adjust for diet, as appropriate.
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carotenoid formulations, on the spatial profile of MP in subjects
with an atypical MP profile characterized by the lack of the typical
central peak. Over an eight week study period, subjects with such
a pre-identified and confirmed atypical spatial profile of their MP
Table 3
Individual MPOD values at each degree of retinal eccentricity for all subjects according to group & visit wise.
No. Group 0.25 0.50 1.0 1.75 3.0
Baseline 4 wks 8 wks Baseline 4 wks 8 wks Baseline 4 wks 8 wks Baseline 4 wks 8 wks Baseline 4 wks 8 wks
1 Group 1 0.86 0.88 0.95 0.88 0.74 0.88 0.02 0.43 0.2 0.24 0.21 0.17 0.2 0.13 0.02
4 Group 1 0.47 0.52 0.53 0.43 0.5 0.51 0.11 0.24 0.19 0.07 0.14 0.13 0.09 0.16 0.06
5 Group 1 0.39 0.39 0.39 0.39 0.39 0.39 0.31 0.3 0.21 0.17 0.26 0.2 0.1 0.35 0.15
7 Group 1 0.14 0.16 0.3 0.13 0.18 0.3 0 0 0.2 0.08 0 0.1 0.16 0.2 0.22
8 Group 1 0.31 0.33 0.28 0.28 0.3 0.34 0.12 0.14 0.23 0.12 0.07 0.17 0.06 0.18 0.15
11 Group 1 0.7 0.72 0.7 0.76 0.72 0.75 0.67 0.55 0.57 0.37 0.3 0.32 0.38 0.26 0.26
12 Group 1 0.29 0.31 0.3 0.3 0.32 0.28 0.2 0.33 0.2 0.06 0.1 0.06 0.03 0.11 0.09
15 Group 1 0.35 0.35 0.27 0.31 0.31 0.18 0.13 0.13 0.05 0.17 0.17 0.01 0.08 0.08 0.01
16 Group 1 0.54 0.54 0.57 0.51 0.51 0.51 0.19 0.19 0.26 0.07 0.07 0.08 0.05 0.05 0.1
19 Group 1 0.53 0.6 0.6 0.61 0.66 0.66 0.29 0.37 0.37 0.1 0.23 0.23 0.25 0.07 0.07
2 Group 2 0.55 0.61 0.75 0.57 0.57 0.57 0.73 0.31 0.44 0.29 0.3 0.27 0.34 0.16 0.39
3 Group 2 0.28 0.39 0.45 0.29 0.25 0.38 0.32 0.17 0.3 0.18 0.19 0.17 0.24 0.07 0.05
9 Group 2 0.23 0.28 0.34 0.27 0.31 0.27 0.36 0.17 0.31 0.23 0.14 0.24 0.34 0.1 0.21
10 Group 2 0.04 0.27 0.28 0.12 0.24 0.25 0.02 0.21 0.25 0 0.15 0.19 0 0.08 0.17
13 Group 2 0.35 0.47 0.57 0.36 0.36 0.51 0 0.17 0.33 0.01 0.13 0.21 0 0.07 0.22
14 Group 2 0.68 0.79 0.8 0.74 0.69 0.7 0.43 0.48 0.48 0.24 0.26 0.26 0.14 0.24 0.24
17 Group 2 0.13 0.1 0.23 0.16 0.09 0.2 0.15 0.16 0.33 0.25 0.1 0.24 0.17 0.15 0.28
18 Group 2 0.65 0.82 0.91 0.67 0.88 0.9 0.36 0.57 0.49 0.19 0.24 0.33 0.07 0.22 0.17
20 Group 2 0.86 0.9 1.12 0.88 0.88 1 0.02 0.43 0.2 0.24 0.21 0.17 0.2 0.13 0.02
31 Group 2 0.29 0.39 0.43 0.31 0.37 0.38 0.24 0.25 0.25 0.14 0.16 0.15 0.13 0.15 0.15
21 Group 3 0.64 0.68 0.51 0.63 0.63 0.46 0.44 0.44 0.43 0.26 0.23 0.14 0.29 0.19 0.13
22 Group 3 0.57 0.55 0.61 0.61 0.55 0.58 0.48 0.35 0.31 0.08 0.15 0.11 0.13 0.25 0.14
23 Group 3 0.5 0.59 0.66 0.47 0.48 0.55 0.35 0.38 0.41 0.14 0.15 0.24 0.15 0.24 0.13
24 Group 3 0.55 0.58 0.61 0.56 0.56 0.57 0.32 0.27 0.33 0.12 0.09 0.13 0.12 0.1 0.13
25 Group 3 0.34 0.34 0.4 0.38 0.38 0.38 0.23 0.23 0.23 0 0 0 0.09 0.09 0.09
26 Group 3 0.57 0.7 0.77 0.57 0.69 0.64 0.4 0.29 0.38 0.26 0.19 0.21 0.2 0.18 0.22
27 Group 3 0.29 0.32 0.34 0.29 0.29 0.31 0.2 0.14 0.15 0.06 0.04 0.06 0.06 0.09 0.08
28 Group 3 0.71 0.92 0.93 0.7 0.69 0.79 0.42 0.57 0.59 0.08 0.18 0.2 0.05 0.16 0.3
29 Group 3 0.29 0.37 0.41 0.3 0.23 0.33 0.1 0.16 0.26 0 0.07 0.05 0.03 0.05 0.14
30 Group 3 0.32 0.45 0.48 0.33 0.34 0.42 0.21 0.3 0.28 0.11 0.1 0.11 0.08 0.12 0.11
Values representmacular pigment optical density (MPOD) values;n¼ 31; 0.25 ¼MPODmeasuredat 0.25 retinal eccentricity; 0.5 ¼MPODmeasured at 0.5 retinal eccentricity;
1 ¼MPOD measured at 1 retinal eccentricity; 1.75 ¼MPOD measured at 1.75 retinal eccentricity; 3 ¼MPOD measured at 3 retinal eccentricity; Group 1 (n ¼ 10): high L
group (L ¼ 20 mg/day, Z ¼ 2 mg/day); Group 2 (n ¼ 10): combined carotenoid group (MZ ¼ 10 mg/day, L ¼ 10 mg/day, Z ¼ 2 mg/day); Group 3 (n ¼ 10): high MZ group
(MZ ¼ 17 mg/day, L ¼ 3 mg/day, Z ¼ 2 mg/day). Of note, at baseline average MPOD at 0.25 was significantly less than average MPOD at 0.5 in the subjects studied here.
Retinal eccentricity























MPOD spatial profile at baseline
MPOD spatial profile at 8 weeks after supplementation
Fig. 2. Mean macular pigment optical density spatial profile of Group 1 at baseline (pre
supplementation) and at 8 weeks (post supplementation). Mean  standard deviation;
n ¼ 10; Group 1: high L group (L ¼ 20 mg/day, Z ¼ 2 mg/day). The smooth line drawn
through the data was achieved using our graphic software Sigma Plot 8.
Table 2
AverageMPOD values at each degree of retinal eccentricity for all subjects according
to group & visit.
Group MPOD Baseline 4 wks 8 wks Time interaction
(p-value)
Group 1 0.25 0.46  0.21 0.48  0.21 0.49  0.22 0.220
Group 1 0.5 0.46  0.23 0.46  0.19 0.48  0.23 0.626
Group 1 1 0.20  0.19 0.27  0.16 0.25  0.14 0.283
Group 1 1.75 0.15  0.10 0.16  0.10 0.15  0.09 0.904
Group 1 3 0.14  0.11 0.16  0.09 0.11  0.08 0.370
Group 2 0.25 0.41  0.27 0.50  0.27 0.59  0.30 0.000
Group 2 0.5 0.44  0.26 0.46  0.28 0.52  0.28 0.016
Group 2 1 0.26  0.23 0.29  0.15 0.34  0.10 0.417
Group 2 1.75 0.18  0.10 0.19  0.06 0.22  0.06 0.218
Group 2 3 0.16  0.12 0.14  0.06 0.19  0.11 0.448
Group 3 0.25 0.48  0.16 0.55  0.19 0.57  0.18 0.005
Group 3 0.5 0.48  0.15 0.48  0.17 0.50  0.15 0.786
Group 3 1 0.32  0.12 0.31  0.13 0.34  0.12 0.596
Group 3 1.75 0.11  0.09 0.12  0.07 0.13  0.08 0.743
Group 3 3 0.12  0.08 0.15  0.07 0.15  0.07 0.522
Values represent mean  standard deviation; n ¼ 31; MPOD ¼ macular pigment
optical density; 0.25 ¼MPOD measured at 0.25 retinal eccentricity; 0.5 ¼MPOD
measured at 0.5 retinal eccentricity; 1 ¼ MPOD measured at 1 retinal eccen-
tricity; 1.75 ¼MPOD measured at 1.75 retinal eccentricity; 3 ¼MPOD measured
at 3 retinal eccentricity; Group 1 (n ¼ 10): high L group (L ¼ 20 mg/day,
Z ¼ 2 mg/day); Group 2: combined carotenoid group (MZ ¼ 10 mg/day,
L ¼ 10 mg/day, Z ¼ 2 mg/day); Group 3: high MZ group (MZ ¼ 17 mg/day,
L ¼ 3 mg/day, Z ¼ 2 mg/day); The p-values represent repeated measures ANOVA for
the 3 study visits (withinesubject effects), with GreenhouseeGesser correction for
lack of sphericity as appropriate.
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were supplemented with one of three different carotenoid formu-
lations, as follows: Group 1: high L group (L¼ 20 mg/day, Z¼ 2mg/
day); Group 2: combined carotenoid group (MZ ¼ 10 mg/day,
L ¼ 10 mg/day, Z ¼ 2 mg/day); Group 3: high MZ group
(MZ ¼ 17 mg/day, L ¼ 3 mg/day, Z ¼ 2 mg/day).
Over the last number of years, reports on the spatial profile of
MP have generated debate. In 1997, Hammond, Wooten and
Snodderly conducted a study in 32 subjects to investigate indi-
vidual variations in the spatial profile of human MP, and concluded
that an exponential decay with eccentricity explained more vari-
ance in the distribution than a Gaussian function (Hammond et al.,
1997). The MP spatial profile has since been described as a central
peak, which decreases with eccentricity to optically undetectable
levels by 10 eccentricity. While it is true that such an exponential
decay still describes the MP profile very well (even in subjects with
“atypical” profiles), recent study has revealed that there are obvious
deviations from a monotonic decline from the central fovea
(Berendschot and van Norren, 2006; Dietzel et al., 2011; Kirby et al.,
2009, 2010; Trieschmann et al., 2003).
Indeed, even in the publication by Hammond et al. in 1997, the
authors noted deviations from an exponential function in 40% of
subjects (Hammond et al., 1997). In 2003, Trieschmann et al,
reported that the spatial profile of MP, assessed using AF, exhibited
four types of distribution, and that MPOD was lower in patients
with AMD (Trieschmann et al., 2003). In 2006, Delori et al.
described bimodal spatial distributions of MP that were charac-
terized by a central peak of highestMP density surrounded by a ring
with high-density values at approximately 0.7 from the fovea. In
the same year, Berendschot and van Norren (2006) confirmed this
finding and reported that both reflectance and AF maps showed
ringlike patterns in the distribution of the MP, and suggested that
such patterns follow the distribution of the inner plexiform layer.
Indeed, the authors reported a distinct ring pattern in over 50% of
subjects, at a mean distance of 0.7 from the foveal centre, and
noted that in a few subjects, the orbit of the ring has an even greater
optical density than did the central peak. Furthermore, Dietzel et al.
reported ringlike structures in circa 20% of subjects, which were
less likely to be seen in subjects with AMD. Dietzel et al. also
described MP distributions (using AF) as intermediate where there
is no strictly monotonic decline from the centre of the fovea to the
periphery, but no explicit ringlike pattern of MP, but where an
implied plateau exists (Dietzel et al., 2011).
In brief, therefore, there is consensus that inter-individual
variability, in terms of the spatial distribution of MP, does exist.
However, the terminology used to classify such variations has
differed, and the terms employed reflect the methodology used to
measure MP.
With HFP, for example, a 2-dimensional profile (silhouette) of
MP is generated, prompting terms such as “central dip” (Kirby et al.,
2010), “minor flanking peaks” (Hammond et al., 1997) or “shoulder”
to describe profiles that do not exhibit the typical monotonic
decline with eccentricity and that are seen in about 40% of subjects
(Hammond et al., 1997).
Using AF, where an “en face” map is generated, the term
“ringlike structure” has been used to describe “...the bimodal
pattern of MPOD [is] visible as a ringlike structure with a central
peak of MPOD surrounded by a ring of increased density” (Dietzel
et al., 2011). We believe the ringlike structures and intermediate
profiles described with AF represent the non-monotonic decays of
MP that we and others have observed using HFP, given the radial
symmetry of MPOD (Hammond et al., 1997). In support of this view
is the observation that the former are seen in approximately 50% of
cases using AF (Berendschot and van Norren, 2006) and the latter
are seen in approximately 40% of cases assessed by HFP (Hammond
et al., 1997). For this reason, and for the purpose of this study, we
have defined an atypical profile as one where MPOD at 0.25 does
not exceed MPOD at 0.5 by more than 0.04 ODU, therefore rep-
resenting a subgroup of AF-generated ringlike structures or inter-
mediate patterns described by Berendschot and van Norren in
a “few” of their subjects (Berendschot and van Norren, 2006).
We report a statistically significant increase in MPOD at 0.25
retinal eccentricity in the combined carotenoid group (Group 2)
and the high MZ group (Group 3), but no increase in MPOD at 0.25
in the high L group (Group 1). With respect to individual responses
and magnitude of responses with in the Groups, it is important to
note that the increase in MPOD, whether expressed in terms of the
proportion of subjects exhibiting a >10% rise or in terms of average
increase in MPOD, at either 0.25 or 0.5 eccentricity, was substan-
tially greater for subjects in Group 2 (i.e. those supplemented with
all three macular carotenoids). Further, Group 2 was unique in that
all subjects in this Group exhibited an increase of at least 10%
(i.e. a clinically meaningful response) at 0.25 eccentricity, and was
Retinal eccentricity
























MPOD spatial profile at baseline
MPOD spatial profile at 8 weeks after supplementation
Fig. 3. Mean macular pigment optical density spatial profile of Group 2 at baseline (pre
supplementation) and at 8 weeks (post supplementation). Mean  standard deviation;
n ¼ 10; Group 2: combined carotenoid group (MZ ¼ 10 mg/day, L ¼ 10 mg/day,
Z ¼ 2 mg/day). The smooth line drawn through the data was achieved using our
graphic software Sigma Plot 8.
Retinal eccentricity























MPOD spatial profile at baseline
MPOD spatial profile at 8 weeks after supplementation
Fig. 4. Mean macular pigment optical density spatial profile of Group 3 at baseline (pre
supplementation) and at 8 weeks (post supplementation). Mean  standard deviation;
n ¼ 10; Group 3: high MZ group (MZ ¼ 17 mg/day, L ¼ 3 mg/day, Z ¼ 2 mg/day). The
smooth line drawn through the data was achieved using our graphic software Sigma
Plot 8.



































































































































YEXER5973_proof ■ 2 June 2012 ■ 5/7
Please cite this article in press as: Nolan, J.M., et al., Macular carotenoid supplementation in subjects with atypical spatial profiles of macular
pigment, Experimental Eye Research (2012), doi:10.1016/j.exer.2012.05.006
also unique in that the average MPOD increase was greater than
100% at this eccentricity (and this compares with only 13% and 22%
in Groups 1 and 3, respectively). MP response at this central retinal
location is of interest to the current investigation and report, given
that the pre-specified hypothesis was that supplementation with
appropriate macular carotenoids could realise the typical central
peak of MP in subjects selected on the basis that they lacked such
(desirable) typical profile at baseline (Kirby et al., 2010). The
research question, therefore, was to determine if subjects not
exhibiting the typical central peak of MP (at baseline) would
respond differently to different macular carotenoid formulations.
We hypothesized that supplementation with MZ (as in Groups 2
and 3) may augment central MP in subjects presenting with our
predefined and non-peaked MP spatial profiles. The rationale,
which informed this hypothesis, was premised on the observation
that MZ, which comprises one-third of the human MP, is the most
centrally located of the macular carotenoids (Bone et al., 1997) (i.e.
the location of the typical central peak of MP (Kirby et al., 2010)).
Of importance to this discussion, macular MZ is produced
primarily by isomerization of macular L, (Neuringer et al., 2004)
thus accounting for lower relative levels of L, and higher relative
levels of MZ, in the central macula, and vice versa in the peripheral
macula (Bone et al., 1988). It is possible, therefore, that the mech-
anism which converts L to MZ at the macula (which may be
enzymatic (Bone et al., 1997) and/or light dependent (Nolan et al.,
2009)) is defective in individuals with no observable typical
central peak of MP. Indeed, the data presented here is consistent
with this hypothesis. Importantly, however, we now confirm that
subjects without a typical central peak in their MP spatial profiles
do respond to a supplement containingMZ (as seen in Groups 2 and
3), but do not respond to a supplement containing high amounts of
L (as seen in Group 1).
The above finding is all the more important, given a recent
publication by our group which showed that individuals at
increased risk of developing AMD (e.g. cigarette smokers and older
people) weremore likely to lack the typical central peak in their MP
spatial profile (see publication by Kirby et al. (2010)). Possible
explanations for this observed association between the atypical
non central-peaked MP spatial profile and increased risk of AMD
may be attributable to this pigment’s physical and chemical prop-
erties. For example, the absence of a central peak of MP suggests
a lack of MZ, and therefore lower antioxidant activity (Foote et al.,
1970; Li et al., 2010) and less short-wavelength light filtering
capacity, when compared to individuals with the typical peak of MP
at the macular epicentre. Indeed, it is these two properties of MP
which have been hypothesized to confer protection against AMD,
and therefore merit discussion (see below).
Moreover, our data is consistent with previous publications in
AMD populations. For example, a study performed by Trieschmann
et al., of 400 subjects (253 with signs of early AMD, 147 without
AMD), reported that eyes afflicted with AMD were more likely to
display low central MPOD when compared to non-AMD subjects
(Trieschmann et al., 2003).
Also, we report that enrichment of MP across the full spatial
profile (i.e. at 0.25, 0.5, 1, 1.75, 3) was achieved only when
subjects were supplemented with all three macular carotenoids (as
per Group 2), suggesting a beneficial and may be even an interac-
tively additive effect of supplementing with all three carotenoids.
Groups 1 and 3 demonstrated little or no response at the eccen-
tricities beyond 0.25 (i.e. at 0.5, 1, 1.75, 3). Of interest, the
preselected eyes with atypical MP profiles were identified in
subjects with high, low and medium levels of baseline MP, thus
suggesting that a lack of L is not the cause of a parallel lack of the
typical central peak in these subjects, and is consistent with our
findings that supplementation with L alone did not increase
MP significantly, whereas supplementation with L, Z and MZ
increased MP significantly (centrally, in the mid periphery and in
the periphery of the macula); whereas supplementation with MZ
alone increased MP significantly (but only at the epicenter).
It is important to point out that an 8-week trial of supplemental
L represents a relatively short time period for such a purpose.
Indeed, other L-supplementation studies have also failed to
significantly augment MP over this time period (Nolan et al., 2011;
Trieschmann et al., 2007). However, the subjects tested here were
atypical by virtue of the fact that they exhibited central dips or
plateaus in their MP spatial profiles, and we sought to specifically
investigate whether such subjects would respond differently to
different carotenoid interventions. Interestingly, only those carot-
enoid formulations in the current study that contained MZ ach-
ieved a rapid response in central MPOD over this time period.
The above findings, however, are consistent with a publication
by Connolly et al. who found that enrichment of MP centrally, and
across its spatial profile, is achieved in subjects (both normal and
AMD-afflicted) supplemented with all three macular carotenoids
(Connolly et al., 2010). This notion is also consistent with in vitro
studies reporting better functionality of the macular carotenoids
when in combination rather than in isolation (Li et al., 2010).
Possible functional implications of enrichment of MP centrally in
subjects lacking the typical central peak of MP (i.e. following
supplementationwith MZ; Group 2 and Group 3), and across its full
spatial profile (Group 3 only) are discussed below. Also, the increase
in central MPOD, seen in Groups 2 and 3, is likely to confer optical
benefits at this location (i.e. enhanced contrast sensitivity and
ameliorated glare disability) (Nolan et al., 2011).
In addition, an increase in central MP will facilitate antioxidant
activity at this retinal locus, whether the subject suffers from AMD
or is at risk of developing this condition. From an antioxidant
perspective, L, Z and MZ are structural isomers of one another and
are characterized, biochemically, by their high number of double-
bonds (Bone et al., 1993). Their supply of readily available electrons
enables these carotenoids to quench reactive oxidative intermedi-
ates (ROIs), thus limiting membrane phosopholipid peroxidation
and attenuating oxidative injury (Sujak et al., 1999). Kirschfeld was
the first to propose the idea that carotenoids protect the macula
against oxidative stress, (Kirschfeld, 1982) and in 1997, Khachik et al.
confirmed the presence of direct oxidation products of L and Z in
human retinal tissue, supporting thehypothesis thatMPdoes indeed
protect against oxidative damage in this tissue (Khachik et al., 1997).
Of note, MP is at its highest concentration in the receptor axon
layer of the foveola and in the inner and outer plexiform layers of
the macula (Snodderly et al., 1984a; Trieschmann et al., 2008). Also,
the concentration of the carotenoids with in each retinal layer
peaks at the foveola (where the ratio of MZ to L and Z is maximum).
Importantly, it is at this central retinal location where ROI
production is greatest. In vitro studies of human RPE cells, subjected
to oxidative stress, have demonstrated enhanced survival of these
cells in the presence of Z and other antioxidants, when compared
with controls (Wrona et al, 2004). Z appears to be a more potent
antioxidant than L (Cantrell et al., 2003) and MZ is yet more effi-
cacious, but only in conjunction with its binding protein (Bhosale
and Bernstein, 2005). Recently, Li et al. demonstrated that
a mixture of L, Z and MZ (in a ratio of 1:1:1) quenches more singlet
oxygen than any of these carotenoids individually but at the same
total concentration (Li et al., 2010). This collective optimization of
antioxidant activity, dependent on the presence of all threemacular
carotenoids, could prevent depletion of MP in such a high oxidative
stress environment. In other words, MP with inadequate quantities
of any of the three macular carotenoids may lack sufficient anti-
oxidant potential to stabilize the pigment in a high oxidative stress
environment, such as the central retina.
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From a light filtering perspective, L is reported to be a superior
filter of blue light when compared to Z, due to its orientation with
respect to the plane of the phospholipid bilayer of the cell
membrane, (Sujak et al, 1999) which is both parallel and perpen-
dicular. In contrast, Z and MZ only exhibit perpendicular orienta-
tion to this layer. However, it is important to note that the different
absorption spectra of these pigments (L, Z and MZ) result in
a collective optimal filtration of blue light at the macula, which
would not be achieved by any of these carotenoids in isolation.
In conclusion, we report that the typical central peak of MP can
be realised in subjects who do not exhibit such typical and peaked
spatial profiles of this pigment, when supplemented with a prepa-
ration containing MZ, by not when supplemented with a formula-
tion lacking this carotenoid. In addition, we found that enrichment
of MP across its spatial profile can be best achieved following
supplementation with all three macular carotenoids (MZ, Z and L).
The implications of our findings, in terms of visual performance
and/or a (photo)-protective effect, warrant study.
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